A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors

Bibliographic Details
Main Authors:	Nathan, P, Judson, I, Padhani, A, Harris, A, Carden, C, Smythe, J, Collins, D, Leach, M, Walicke, P, Rustin, G
Format:	Journal article
Published:	2008

Similar Items

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
by: Nathan, P, et al.
Published: (2012)

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
by: Nathan, P, et al.
Published: (2007)

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
by: Zweifel, M, et al.
Published: (2009)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
by: Rustin, G, et al.
Published: (2010)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
by: Rustin, G, et al.
Published: (2003)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
by: Lunt, S, et al.
Published: (2011)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
by: Jane Lunt, S, et al.
Published: (2011)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
by: Zweifel, M, et al.
Published: (2011)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
by: Meyer, T, et al.
Published: (2009)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
by: Brooks, A, et al.
Published: (2003)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
by: Tozer, G, et al.
Published: (2001)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
by: Galbraith, S, et al.
Published: (2001)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
by: Thomson, P, et al.
Published: (2006)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
by: Prise, V, et al.
Published: (2002)

Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography
by: Gitte Mampaey, et al.
Published: (2022-11-01)

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.
by: Maxwell, R, et al.
Published: (2002)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
by: Tozer, G, et al.
Published: (2009)

Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility
by: Zhi-Hao Chen, et al.
Published: (2023-02-01)

3D-QSAR Study of Combretastatin A-4 Analogs Based on Molecular Docking
by: Hongrui Song, et al.
Published: (2011-08-01)

Early Effects of Combretastatin A4 Phosphate Assessed by Anatomic and Carbogen-Based Functional Magnetic Resonance Imaging on Rat Bladder Tumors Implanted in Nude Mice
by: Carole D. Thomas, et al.
Published: (2006-07-01)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
by: Stratford, MR, et al.
Published: (2012)

Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity
by: Tarek S. Ibrahim, et al.
Published: (2020-11-01)

Self-Assembled Amphiphilic Fluorinated Random Copolymers for the Encapsulation and Release of the Hydrophobic Combretastatin A-4 Drug
by: Matteo Calosi, et al.
Published: (2022-02-01)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
by: Franziska Reipsch, et al.
Published: (2021-12-01)

Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
by: Bonan Zhao, et al.
Published: (2021-05-01)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection
by: Stratford, M, et al.
Published: (2011)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
by: Stratford, MR, et al.
Published: (2011)

Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4
by: Azizah M. Malebari, et al.
Published: (2021-10-01)

Synthesis and Cytotoxic Activity of Combretastatin A-4 and 2,3-Diphenyl-2<i>H</i>-indazole Hybrids
by: Jaime Pérez-Villanueva, et al.
Published: (2021-08-01)

Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest.
by: Daniel Tarade, et al.
Published: (2017-01-01)

New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3<i>H</i>)-benzothiazolones
by: Gjorgji Atanasov, et al.
Published: (2021-12-01)

The Polar Lipid Fraction E from <i>Sulfolobus acidocaldarius</i> Can Be Used as Liposomal Drug Stabilizing Agents to Reduce the Leakage of the Antivascular Drug Combretastatin A4 Disodium Phosphate from Tetraether/Diester Hybrid Archaeosomes
by: Varsha P. Daswani, et al.
Published: (2021-12-01)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
by: Stratford, MR
Published: (2008)

Molecular docking of combretastatin derivatives to combat human cancer cells
by: Kshitij Chitnis, et al.
Published: (2024-01-01)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
by: Gökçe Şeker Karatoprak, et al.
Published: (2020-05-01)

Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
by: Florian Schmitt, et al.
Published: (2019-01-01)

Li4GeO4-Li2CaGeО4 phase equilibria and Li2+xCa1-xGeO4 solid solutions
by: V. Nikolov, et al.
Published: (2024-04-01)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
by: Alla V. Lipeeva, et al.
Published: (2014-06-01)

The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects
by: Cengiz Alagöz, et al.
Published: (2016-10-01)

Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity
by: Haruka Orihara, et al.
Published: (2023-04-01)